Merck plans to double manufacturing capacity for its antiviral pill to treat Covid-19 next year as governments scramble to procure a treatment that a late-stage trial showed cuts hospitalisation and death rates in half.
默克(Merck)計劃明年將其治療新冠的抗病毒藥物的產能提高一倍。目前各國政府正競相采購這種藥物，一項后期臨床試驗顯示它將住院率和死亡率降低了一半。
您已閱讀5%（293字），剩余95%（5372字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。